Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04544410 · ClinicalTrials.gov registry record · Phase 2
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
A Phase 2 study, sponsored by Spruce Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT04544410 is a Phase 2 study that was terminated before completion, run by Spruce Biosciences. The registered enrollment target is 100 participants.
The verdict
NCT04544410, a Phase 2 study, was terminated before completion, sponsored by Spruce Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
An investigation of the ability of Tildacerfont to reduce supraphysiologic glucocorticoid dosing in classic Congenital adrenal hyperplasia (CAH) subjects up to 76 weeks of treatment. Optional open label extension up to 240 weeks.
Interventions
- DRUG Tildacerfont/Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-02-22 |
| Est. Completion | 2025-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04544410
The ClinicalTrials.gov registry entry for NCT04544410 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spruce Biosciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tildacerfont/Placebo is the first listed.
NCT04544410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04544410 about?
NCT04544410 is a clinical study titled "A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH". An investigation of the ability of Tildacerfont to reduce supraphysiologic glucocorticoid dosing in classic Congenital adrenal hyperplasia (CAH) subjects up to 76 weeks of treatment. Optional open label extension up to 240 weeks.
What is the current status of trial NCT04544410?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2021-02-22. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT04544410?
The interventions under investigation include: Tildacerfont/Placebo (DRUG).
Who is sponsoring clinical trial NCT04544410?
This trial is sponsored by Spruce Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.